Evon Jude, Sarah Jaboury, Qing Ze Fang, Josephine Stewart, Frances Barnett, Bianca Devitt et al. Real‐World Toxicity and Outcomes of KEYNOTE‐522‐Style Neoadjuvant Pembrolizumab for Triple‐Negative Breast Cancer in Australia. // Asia-Pacific Journal of Clinical Oncology. – 2026. – DOI: 10.1111/ajco.70223. – URL: https://onlinelibrary.wiley.com/doi/10.1111/ajco.70223?af=R
Evon Jude, Sarah Jaboury, Qing Ze Fang, Josephine Stewart, Frances Barnett, Bianca Devitt, & Belinda Yeo (2026). Real‐World Toxicity and Outcomes of KEYNOTE‐522‐Style Neoadjuvant Pembrolizumab for Triple‐Negative Breast Cancer in Australia. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70223
Evon Jude, et al. “Real‐World Toxicity and Outcomes of KEYNOTE‐522‐Style Neoadjuvant Pembrolizumab for Triple‐Negative Breast Cancer in Australia.” Asia-Pacific Journal of Clinical Oncology, 2026. doi:10.1111/ajco.70223.
@article{Jude2026,
title = {Real‐World Toxicity and Outcomes of KEYNOTE‐522‐Style Neoadjuvant Pembrolizumab for Triple‐Negative Breast Cancer in Australia},
author = {Jude, Evon and Jaboury, Sarah and Fang, Qing Ze and Stewart, Josephine and Barnett, Frances and Devitt, Bianca and Yeo, Belinda},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70223},
url = {https://onlinelibrary.wiley.com/doi/10.1111/ajco.70223?af=R}
}